PT - JOURNAL ARTICLE AU - Alex M. Jaeger AU - Lauren E. Stopfer AU - Emma A. Sanders AU - Demi A. Sandel AU - William A. Freed-Pastor AU - William M. Rideout III AU - Santiago Naranjo AU - Tim Fessenden AU - Peter S. Winter AU - Ryan E. Kohn AU - Jason Schenkel AU - Sean-Luc Shanahan AU - Alex K. Shalek AU - Stefani Spranger AU - Forest M. White AU - Tyler Jacks TI - Deciphering the tumor-specific immunopeptidome <em>in vivo</em> with genetically engineered mouse models AID - 10.1101/2021.06.30.450516 DP - 2021 Jan 01 TA - bioRxiv PG - 2021.06.30.450516 4099 - http://biorxiv.org/content/early/2021/07/01/2021.06.30.450516.short 4100 - http://biorxiv.org/content/early/2021/07/01/2021.06.30.450516.full AB - Effective immunosurveillance of cancer requires the presentation of peptide antigens on major histocompatibility complex Class I (MHC-I). Recent developments in proteomics have improved the identification of peptides that are naturally presented by MHC-I, collectively known as the “immunopeptidome”. Current approaches to profile tumor immunopeptidomes have been limited to in vitro investigation, which fails to capture the in vivo repertoire of MHC-I peptides, or bulk tumor lysates, which are obscured by the lack of tumor-specific MHC-I isolation. To overcome these limitations, we report here the engineering of a Cre recombinase-inducible affinity tag into the endogenous mouse MHC-I gene and targeting of this allele to the KrasLSL-G12D/+; p53fl/fl (KP) mouse model (KP; KbStrep). This novel approach has allowed us to isolate tumor-specific MHC-I peptides from autochthonous pancreatic ductal adenocarcinoma (PDAC) and lung adenocarcinoma (LUAD) in vivo. With this powerful analytical tool, we were able to profile the evolution of the LUAD immunopeptidome through tumor progression and show that in vivo MHC-I presentation is shaped by post-translational mechanisms. We also uncovered novel, putative LUAD tumor associated antigens (TAAs). Many peptides that were recurrently presented in vivo exhibited very low expression of the cognate mRNA, provoking reconsideration of antigen prediction pipelines that triage peptides according to transcript abundance. Beyond cancer, the KbStrep allele is compatible with a broad range of Cre-driver lines to explore antigen presentation in vivo in the pursuit of understanding basic immunology, infectious disease, and autoimmunity.Competing Interest StatementT.J. is a member of the Board of Directors of Amgen and Thermo Fisher Scientific, and a co-Founder of Dragonfly Therapeutics and T2 Biosystems. T.J. serves on the Scientific Advisory Board of Dragonfly Therapeutics, SQZ Biotech, and Skyhawk Therapeutics. T.J. is also President of Break Through Cancer. His laboratory currently receives funding from Johnson &amp; Johnson and The Lustgarten Foundation, and funds from the Lustgarten Foundation supported the research described in this manuscript. None of these affiliations influenced the work conducted or analysis of data presented in this manuscript.